These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 30111966)
21. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans. Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C Front Pharmacol; 2019; 10():196. PubMed ID: 30983993 [TBL] [Abstract][Full Text] [Related]
22. The public funding of expensive cancer therapies: synthesizing the "3Es"--evidence, economics, and ethics. Kirby J; Somers E; Simpson C; McPhee J Organ Ethic; 2008; 4(2):97-108. PubMed ID: 18839752 [TBL] [Abstract][Full Text] [Related]
23. Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada. MacPhail C; Snow S Curr Oncol; 2022 Mar; 29(3):2064-2072. PubMed ID: 35323366 [TBL] [Abstract][Full Text] [Related]
24. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups. Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233 [TBL] [Abstract][Full Text] [Related]
25. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications. Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899 [TBL] [Abstract][Full Text] [Related]
26. Access to drugs for cancer: Does where you live matter? Menon D; Stafinski T; Stuart G Can J Public Health; 2005; 96(6):454-8. PubMed ID: 16350873 [TBL] [Abstract][Full Text] [Related]
27. The timing of drug funding announcements relative to elections: a case study involving dementia medications. Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820 [TBL] [Abstract][Full Text] [Related]
28. Value assessment of oncology drugs using a weighted criterion-based approach. Ezeife DA; Dionne F; Fares AF; Cusano ELR; Fazelzad R; Ng W; Husereau D; Ali F; Sit C; Stein B; Law JH; Le L; Ellis PM; Berry S; Peacock S; Mitton C; Earle CC; Chan KKW; Leighl NB Cancer; 2020 Apr; 126(7):1530-1540. PubMed ID: 31860138 [TBL] [Abstract][Full Text] [Related]
29. Use of product listing agreements by Canadian provincial drug benefit plans. Morgan SG; Friesen MK; Thomson PA; Daw JR Healthc Policy; 2013 May; 8(4):45-55. PubMed ID: 23968637 [TBL] [Abstract][Full Text] [Related]
30. Impact of rarity on Canadian oncology health technology assessment and funding. Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560 [TBL] [Abstract][Full Text] [Related]
31. Pricing of alcohol in Canada: A comparison of provincial policies and harm-reduction opportunities. Giesbrecht N; Wettlaufer A; Thomas G; Stockwell T; Thompson K; April N; Asbridge M; Cukier S; Mann R; McAllister J; Murie A; Pauley C; Plamondon L; Vallance K Drug Alcohol Rev; 2016 May; 35(3):289-97. PubMed ID: 26530717 [TBL] [Abstract][Full Text] [Related]
32. "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada. Driedger SM; Cooper E; Annable G; Brouwers M Int J Health Plann Manage; 2018 Apr; 33(2):e485-e499. PubMed ID: 29417619 [TBL] [Abstract][Full Text] [Related]
33. Clinician Perspectives of COVID-19-Related Cancer Drug Funding Measures in Ontario. Naipaul RD; Mercer RE; Chan KKW; Yeung L; Forbes L; Gavura S Curr Oncol; 2021 Feb; 28(2):1056-1066. PubMed ID: 33652898 [TBL] [Abstract][Full Text] [Related]
34. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma. Chabot I; Rocchi A Value Health; 2010; 13(6):837-45. PubMed ID: 20561332 [TBL] [Abstract][Full Text] [Related]
35. Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study. Lexchin J PLoS One; 2019; 14(2):e0212399. PubMed ID: 30768629 [TBL] [Abstract][Full Text] [Related]
36. Engaging the Canadian public on reimbursement decision-making for drugs for rare diseases: a national online survey. Polisena J; Burgess M; Mitton C; Lynd LD BMC Health Serv Res; 2017 May; 17(1):372. PubMed ID: 28549479 [TBL] [Abstract][Full Text] [Related]
37. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis. Lexchin J BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631 [TBL] [Abstract][Full Text] [Related]
38. Milestones, barriers and beacons: Shared decision making in Canada inches ahead. Légaré F; Stacey D; Forest PG; Coutu MF; Archambault P; Boland L; Witteman HO; LeBlanc A; Lewis KB; Giguere AMC Z Evid Fortbild Qual Gesundhwes; 2017 Jun; 123-124():23-27. PubMed ID: 28532628 [TBL] [Abstract][Full Text] [Related]
39. Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. Berry SR; Bell CM; Ubel PA; Evans WK; Nadler E; Strevel EL; Neumann PJ J Clin Oncol; 2010 Sep; 28(27):4149-53. PubMed ID: 20697077 [TBL] [Abstract][Full Text] [Related]
40. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review. Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]